Ascendis Pharma A/S reported a net loss of €131 million for Q1 2024, up from a loss of €110 million in Q1 2023. The filing reflects their financial position as of March 31, 2024, with total assets of €802 million and equity of -€238 million, indicating a significant ongoing financial challenge.